Circulating Tumor Cells Market

Global Circulating Tumor Cells Market Size (2023 to 2028)

As per our research report, the global circulating tumor cells market is predicted to rise at a compound annual growth rate (CAGR) of 13.22% from 2023 to 2028. As a result, the market size is expected to grow to USD 19.02 billion by 2028 from USD 10.22 billion in 2023.

Global Circulating Tumor Cells Market Share Insights:

• Based on technology, the CTC enrichment methods segment dominated the market and accounted for the largest share of the market in 2022.
• Based on product, the devices and systems segment had the most dominant share of 40% of the market in 2022.
• Based on end-user, the research and academic institutes segment led the market and occupied a share of 68.9% in the global market in 2022.
• The North American circulating tumor cells market was valued at USD 2.73 billion in 2022. 
• The circulating tumor cells market in Europe held a notable share of the worldwide market in 2022. 

The Circulating tumor cells (CTCs) are a rare subset of cells in the blood of patients with solid tumors which function as a seed for metastasis, which metastasizes in the bloodstream as multicellular clusters or individual migrating CTCs to preserve primary tumor heterogeneity and mimic tumor properties. CTCs may be used in clinical settings as a component of liquid biopsies. In addition, 3D organoid cultures that could be used for drug screening, disease modeling, genome editing, tumor immunity, and organoid biobanks can be created using CTCs.

Impact of COVID-19 on the global circulating tumor cells market:

The global CTC has had a positive effect of Covid-19 pandemic since it shed light on preventable cancer deaths by shifting the mindset to the healthcare system due to the significantly increased tumor burden during COVID-19, which opened a new window of opportunity for players in the CTC diagnostics market to offer innovative products adapted to the needs for the specific treatment procedure.

MARKET DRIVERS:

The growing incidence of cancer, increasing preference for minimally invasive diagnostic methods, the growing potential of CTCs in diagnosis and treatment, and the growing awareness of cancer are a few of the factors fuelling the circulating tumor cells market.

Moreover, applications of CTCs in pre-diagnosis, intra-and-post-treatment, and pre-treatment in terms of efficiency and speed are expected to provide lucrative growth opportunities for the market growth of CTC. Another reason for its great popularity could be the various advantages of CTC treatment, including limited trauma, rapid recovery, minimally invasive detection of tumors, and its non-invasive nature. In addition, the role of various government agencies in investing funds, extensive research, and advances in biomedical imaging and bioengineering technology is expected to drive the market positively.

Technological advancements to propel the circulating tumor cells market.

The increasing use in medical research for developing models of cell culture, which help in disease modeling, drug screening, tumor immunity, and genome editing, increasing R&D in circulating tumor cell technology, and growing awareness among healthcare professionals and patients on the importance of early diagnosis of cancer lead to increased demand for technological advancements in CTC treatments like especially 3D organoid cultures which are increasingly being used for organoid biobanking, drug screening, genome editing, and disease modeling.

The growing demand for preventative medicine and complementary diagnostics, growing demand for minimally invasive diagnostic procedures for the treatment of various circulating tumor cells and other related disorders, growing demand for companion diagnostics, increased demand for precision medicine, development of targeted therapies, and discovery of new biomarkers for various ailments to fulfill unmet needs for cancer treatment are further anticipated to drive the market growth.

MARKET RESTRAINTS:

A few factors might lead to the downfall of the CTC market. The strict regulatory framework, technical difficulties in CTC detection, cost containment measures, lack of knowledge about advanced CTC technologies, and time-consuming requirements for product launch approvals. Other factors include poor characterization, high diagnostic and CTCs costs, increasing prevalence of point-of-care testing, and reluctance to adopt advanced CTC technologies, which are expected to hamper market growth further.

REPORT COVERAGE:

This research report on the global circulating tumor cells market has been segmented and sub-segmented based on technology, product, end-user, and region.

Circulating Tumor Cells Market - By Technology:

• CTC Enrichment Methods
  • Positive Enrichment
  • Negative Enrichment
  • Others
• CTC Detection Methods
  • Immunocytochemical Technology
  • Molecular (RNA)-Based Technology

Based on technology, the CTC enrichment methods segment is anticipated to lead the market during the forecast period. These methods allow the non-invasive collection of CTCs from the blood and the withdrawal of a blood sample to provide important information in cancer detection and control. In addition, this system of CellSearch is used for the determination of the prognosis of patients by using the cell surface marker Epithelial Cell Adhesion Molecule to enrich CTCs.

On the other hand, the CTC detection segment is estimated to register a healthy CAGR during the forecast period. The most used technique for CTC detection, based on CTC-specific cell surface markers, is immunological isolation. The techniques used by Immunocytochemical technology either employ positive selection, which focuses on tumor-associated antigens expressed by CTCs, or adverse selection, which eliminates blood cells with typical leukocyte indicators.

Circulating Tumor Cells Market - By Product:

• Kits & Reagents
• Blood Collection Tubes
• Devices or Systems

Based on the product, the devices or systems segment will dominate the market during the forecast period. This can be attributed to the introduction of fabricated glass microchips to overcome challenges, the presence of an extensive portfolio in this category, and improved technical integrity for mass production.

The blood collection tubes segment is also anticipated to account for a substantial global market share during the forecast period. The blood collection tubes are used to identify tumor cells in a blood sample and collect and store whole human blood samples for CTC evaluation. These CTCs are identified and counted by flow cytometry, help predict prognosis and determine response to chemotherapy.

Circulating Tumor Cells Market - By End-User:

• Research & Academic Institutes
• Hospital & Clinics
• Diagnostic Centers

The research segment is expected to dominate the market owing to the recent shifting of focus to the isolation and characterization of circulating tumor cells for providing essential opportunities in predictive testing research since the enumeration of circulating tumor cells, overall, is a research tool. Therefore, the items available on the market are mainly made for use in research settings because this field has significantly enhanced cancer studies.

The hospital segment is anticipated to represent most of the CTC market because of improved treatment using advanced solutions provided by the hospitals, high-profit margins, and purchasing products at lower prices.

Circulating Tumor Cells Market - By Region:

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

North America dominated the market in 2022. This is attributed to highly significant technological convergence in the field of cancer research, well-established healthcare infrastructure, the addition of advanced diagnostic technologies, and alarming rates of Current statistics on cancer incidence, survival, and mortality. Also, the various strategies undertaken by the players to improve their market share and encouragement of research on cancer in this area due to the growing prevalence of cancer diseases can be attributed to the large US market share.

The presence of a population with a high susceptibility to cancer, the existence of a sizeable cancer-prone population, an increase in market penetration rates, the high frequency of technologically advanced cancer care infrastructure, and a state-of-the-art cancer care infrastructure are some of the significant factors behind the high participation of activities of key players like Aviva Biosciences, Apocell, Inc., Biocept, Inc. Therefore, the market for circulating tumor cells is rising due to their efficiency and practical application. Additionally, the United States and demanding more technologically improved cancer care infrastructure.

The European market is also expected to show growth potential for the growing demand for circulating tumor cells with the increasing prevalence of cancer diseases and market players with technological advancements in healthcare industries.

The region of Asia-Pacific is estimated to experience lucrative growth owing to growing patient awareness of early cancer detection, risk assessment, and highly unmet diagnostic needs among patients.

Among Latin America, the Middle East, and Africa regions, South Africa is expected to dominate the market due to increasing disposable income and the high prevalence of chronic diseases. On the other hand, The Middle East & Africa Circulating Tumor Cell (CTC) market is experiencing new prospects due to the presence of cutting-edge technology and strategic moves by players.

TOP COMPANIES IN THIS MARKET:

Companies playing a key role in the global circulating tumor cells market profiled in this report are Bio-Techne Corporation, Janssen Diagnostics LLC, Advanced cell Diagnostics Inc., ApoCell Inc., Celltraffix Inc., Aviva Biosciences, Biocept Inc., Clearbridge Biomedics, Fluxion Biosciences, IVDiagnostics, and Stemcell Technologies Inc.

RECENT HAPPENINGS IN THE MARKET:

• In 2021, Menarini Silicon Biosystems launched the CellMag product for the manual enrichment and detection of uncommon circulating tumor cells.
• In 2021, Datar Cancer Genetics announced the publication of the internationally recognized MedTech Innovation Briefing (MIB) from the United Kingdom's National Institute for Health and Care Excellence.
• Biolidics and Sysmex have agreed to collaborate on developing LDT for cancer diagnosis in 2019.
• In Oct 2022, a team from the University of Geneva (UNIGE) found a way to overcome colorectal cancer, one of the most common cancers among the population, through a chemotherapy-based treatment, using an optimized combination of drugs of tyrosine kinase inhibitors to attack cancer cells.
• In July 2022, UCF researchers discovered a new way to track metastatic cancer cells, helping in the early identification of cancer and providing more treatment options to patients. Chaperonin is a new marker for cancer cells in the blood, a protein complex given to patients for a more unambiguous indication of the spread of cancer.